INmune Bio (INMB) Osake Kurssi

INmune Bio Inc's business model focuses on developing novel immunotherapies to combat cancer and neurodegenerative diseases. The company utilizes a unique approach called DN-TNFα-based cancer immunotherapy, which harnesses the power of the immune system to target and eliminate cancer cells. INmune Bio's therapies aim to enhance immune responses and provide long-term protection against tumor growth. The company also conducts research on neuroinflammation and neurodegeneration with the goal of developing therapies to treat Alzheimer's and Parkinson's diseases. By leveraging cutting-edge science, INmune Bio Inc aims to revolutionize the field of immunotherapy and improve patient outcomes in the fight against cancer and neurodegenerative disorders.

INmune Bio Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of INmune Bio Inc in the market are Immune Pharmaceuticals Inc, Innovus Pharmaceuticals Inc, and Immunomedics Inc.

INmune Bio Inc has achieved several significant milestones. The company successfully completed its Phase I clinical trial for its drug candidate INB03, demonstrating its safety and tolerability in patients with advanced solid tumors. INmune Bio also received Fast Track designation from the U.S. FDA for its lead drug candidate, XPro1595, for the treatment of Alzheimer's disease. Furthermore, the company has received grant funding from the National Institutes of Health (NIH) to support the clinical development of XPro1595. These achievements highlight the progress and potential of INmune Bio Inc in the field of immunotherapy and positions them as a key player in addressing challenging diseases like Alzheimer's.

INmune Bio Inc is primarily present in the United States.

INmune Bio Inc represents a strong commitment to innovation and advancing the field of immunotherapy. The company is guided by a corporate philosophy centered around harnessing the power of the immune system to develop novel treatments for cancer and other diseases. INmune Bio Inc strives to deliver cutting-edge therapies that can make a significant impact on patients' lives. With a focus on precision medicine and personalized immunotherapies, the company is dedicated to providing hope and improved outcomes for individuals facing challenging medical conditions. INmune Bio Inc's values of integrity, scientific excellence, and patient-centricity drive their pursuit of groundbreaking solutions in the field of immunotherapy.

Analyytikot asettavat tällä hetkellä INmune Bio-osakkeelle keskimääräisen tavoitehinnan 5,36 USD (mediaani: 5,61 USD), mikä merkitsee +190,2 % viimeisimpään hintaan verrattuna. Konsensus perustuu 10 analyytikkoarvioon.

INmune Bio Analyytikkojen kursstavoitteet 2026

10 analyytikkoa arvioi tällä hetkellä INmune Bio-osaketta: 9 suosittaa ostoa, 1 pitoa ja 0 myyntiä.

INmune Bio Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla INmune Bio-osake noteerataan hintaan 1,65 EUR (1,85 USD).

INmune Bio-osake (INMB) on listattuna 1 pörssissä, muun muassa: NASDAQ (INMB).

INmune Bio Inc is a biopharmaceutical company that focuses on researching and developing novel immunotherapy products. The company is based in La Jolla, California and works with an experienced team of scientists and researchers to develop innovative solutions for diseases such as Alzheimer's, cancer, and autoimmune diseases. The business model of INmune Bio Inc includes various divisions that aim to develop immunotherapies. One of the main divisions is the research of drugs that support and enhance the body's natural immune response. The company has developed several products based on this research, including INKmune, XPro1595, and INB03. INKmune® is a unique immune activator that supports the immune system in fighting diseases such as cancer and Alzheimer's. The medication aims to activate the immune system and strengthen the body's defenses to destroy cancer cells and Alzheimer's plaques. XPro1595 is a potential medication for treating neuroinflammations that occur in Alzheimer's disease and other neurodegenerative diseases. It has been successfully used in clinical trials and proven to be effective. INB03 is an antibody that inhibits the protein CD47, which cancer cells use as a shield to protect themselves from the body's immune response. INB03 was developed to strengthen the body's immune system and build natural immunity against cancer cells. INmune Bio Inc also has a pipeline of products in development that target the research of immunotherapy solutions for other diseases such as autism and multiple sclerosis. The company specializes in collaborating with other companies and research institutions to advance its research and product development. It has already signed a number of partnership agreements to expand its pipeline of products. INmune Bio Inc employs a broad marketing strategy to promote its products. The company utilizes digital media and various marketing channels to market its products to potential customers and healthcare organizations. Overall, INmune Bio Inc is a biopharmaceutical company specializing in the development of immunotherapeutic products for various diseases. The company has positioned itself as a leader in the research and development of immunotherapies and employs a broad marketing strategy to promote its products.

Liikevaihtoa ei voida laskea INmune Bio:lle tällä hetkellä.

odotettu voitto INmune Bio on −14,62 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

INmune Bio:n hinta-voitto-suhde (P/E) on tällä hetkellä −3,35. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan INmune Bio-osakkeen arvostusta.

P/S-suhdetta ei voida laskea INmune Bio:lle tällä hetkellä.

INmune Bio:n Eulpool-laatuscore on 3/10.

INmune Bio:n ISIN on US45782T1051. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

INmune Bio:n WKN on A2PCBU. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

INmune Bio:n ticker on INMB. Tämä pörssinoteeraus käytetään INmune Bio-osakkeiden kauppaan pörssissä.